Utah Medical Products

Utah Medical Products, Inc. engages in the manufacturing, developing, and marketing of disposable and reusable medical devices. It focuses on the healthcare of women and babies. Its products are used for blood pressure monitoring and blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology. The company was founded on April 21, 1978 and is headquartered in Midvale, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S.

Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend

UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.

Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales

SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024

SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

Utah Medical Products, Inc. Announces Quarterly Dividend

Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.

Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales

SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024

Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.

Zacks Initiates Coverage of UTMD With Neutral Recommendation

SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. Summary of results.

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024

FIGS

These beaten-down stocks have lots of long-term potential.

2 Beaten-Down Stocks That Could Be Ready to Soar

SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management's beginning of year projections.

UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance

SALT LAKE CITY, UT / ACCESSWIRE / October 31, 2023 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on January 3, 2024 to shareholders of record at the close of business on December 15, 2023. This is a 1.7% increase over the prior regular quarterly cash dividend.

Utah Medical Products, Inc. Increases Regular Quarterly Dividend

SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections.

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023

Utah Medical Products stock has dropped 14% and is at its lowest point this year due to ongoing lawsuits regarding its Filshie clip system. The lawsuits do pose a risk to UTMD's stock price, and a negative outcome could further impact the company's equity. Despite the risks, UTMD's long-term economics and attractive proposition in multiple markets are bullish features.

Utah Medical Products: Long-Term Positives, But Filshie Clip Overhang Can't Be Ignored

SALT LAKE CITY, UT / ACCESSWIRE / August 31, 2023 / As Utah Medical Products, Inc.'s (NASDAQ:UTMD's) stockholders know, the following disclosure was included in the Company's 2022 SEC 10-K annual report, released in March 2023: "In late 2021, after the Filshie clip had been used in the U.S. for 25 years and implanted in millions of women, a clip migration lawsuit was filed in Texas. Subsequently, the same law firm solicited and recruited claimants in other states.

UTMD Updates Status of Filshie Product Liability Lawsuits in the U.S.

SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections.

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023

Utah Medical Products comes with high returns on capital and projected earnings growth into FY'25. The company has compounded earnings at a rate of 2.8x that of revenue since 2021. Net-net, reiterate buy, eyeing a long-term price target of $223 per share.

Utah Medical Products: Earnings Power, Asset Factors Warrant Further Re-Rating

SALT LAKE CITY, UT, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - In the first calendar quarter (1Q) of 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals previously announced for calendar year 2023.

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023

Utah Medical Products: Recycling Capital Well, Long-Term Gains On The Table

SALT LAKE CITY, UT, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. (Nasdaq: UTMD) finished the calendar year with a solid fourth quarter (4Q) performance, which allowed financial results for the year 2022 exceeding management's beginning of year projections, despite many challenges.

UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance

UTMD is a relatively undercovered, unexploited name that historically trades within a narrow trading range, within a defensive sector. With this in mind, we wanted to see how it fits in within a cross-asset balanced portfolio setup.

Is Utah Medical Products Suitable As A Defensive Overlay In Equity Portfolios?

SALT LAKE CITY, UT, Oct. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - In the third calendar quarter (3Q) of 2022, despite significant cost inflation, supply chain disruption, litigation expenses and negative impact of a stronger U.S. Dollar on foreign currency sales, Utah Medical Products, Inc. (Nasdaq: UTMD) continued to achieve financial results which were better than those anticipated in its beginning of year projections.

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022

SALT LAKE CITY, UT , July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --UTMD achieved second calendar quarter (2Q) and first half (1H) 2022 financial results better than those anticipated in its beginning of year projections.

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022

SALT LAKE CITY, UT, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – In the first calendar quarter (1Q) of 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals for calendar year 2022.

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022

Salt Lake City, Utah, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- The fourth calendar quarter (4Q) of 2021 financial results demonstrate Utah Medical Products, Inc.'s (Nasdaq: UTMD's) continuing performance improvement despite many challenges related to the corona virus pandemic including on-again/off-again restrictions on so-called nonessential medical procedures, supply chain disruption, high inflation on raw materials, freight and labor costs as well as a continued shortage of labor and higher employee turnover. Because of UTMD's unusual dip in 2020 financial performance, UTMD management continues to report quarterly income statement results compared to the same periods not only for 2021 compared to 2020, but also for 2021 compared to the pre-pandemic year of 2019. The Company exceeded its stated objective early in 2021 to try to fully recover back to its 2019 financial performance. Please see the income statements for all three years on the last page of this report.

UTMD Reports Audited Year 2021 and Fourth Quarter Financial Performance

SALT LAKE CITY, UT / ACCESSWIRE / November 2, 2021 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a special cash dividend of two dollars ($2.00) per share of common stock payable on December 29, 2021 to stockholders of record at the close of business on December 15, 2021. This dividend replaces the normal quarterly dividend, and will be paid in December rather than in early 2022.

News for Utah Medical Products Stock (UTMD)